Abstract Tropomyosins (Tms) are a family of highly conserved actin-binding proteins that play critical roles in a variety of processes, most notably, in the regulation of muscle contraction and relaxation. It is well known that different Tm isoforms have distinct functions and that altered expression of Tm isoforms could lead to changes in cardiac structure and function. To precisely define Tm isoform expression in the human heart, towards a better understanding of their functional roles, we have employed top-down mass spectrometry for in-depth proteomic characterization of Tm isoforms. Using a minimal amount of human heart tissue from rejected donor organs, we confirmed the presence of multiple Tm isoforms including a-Tm, b-Tm and j-Tm in the human heart, with a-Tm being the predominant isoform, followed by minor isoforms of b-Tm and j-Tm. Interestingly, our data revealed regional variations of Tm isoforms and post-translational modifications in the human heart. Specifically, the expression level of j-Tm was highest in the left atrium but nearly undetectable in the left ventricle. The phosphorylation level of a-Tm ( p a-Tm) was significantly higher in the atria than it was in the ventricles. The sequences of all Tm isoforms were characterized and the sites of post-translational modifications were localized. Clearly, top-down mass spectrometry is an attractive method for comprehensive characterization of Tm isoforms and post-translational modifications since it can universally detect and quantify all types of protein modifications without a priori knowledge and without the need for specific antibodies.
Introduction
Tms are a family of actin-binding proteins found in virtually all eukaryotic cells, playing critical roles in a variety of processes including striated muscle contraction and relaxation (Gunning 2008; Perry 2001) . Tm is a dimer with a-helical coiled-coil structure that forms a head-to-tail polymer along the major groove of actin filaments. Tm, actin and troponin complex (troponin I, troponin T, troponin C) are five major proteins composing the thin filament in striated muscle. As one of the regulatory proteins in the thin filament, Tm, together with troponin complex, blocks the myosin binding sites on the actin filament, preventing crossbridge formation and, consequently, regulating muscle contraction in a calcium-dependent manner (Gunning 2008; Jagatheesan et al. 2010a, b; Perry 2001) .
Human Tm exhibits significant complexity with a number of isoforms arising from different genes and alternative splicing events in addition to post-translational modifications (PTMs) (Denz et al. 2004; Gunning 2008; Perry 2001; Wieczorek et al. 1988) . It is encoded by four different genes (TPM1, TPM2, TPM3, and TPM4) each of which is known to give rise to multiple isoforms via alternative splicing events (Marston and Redwood 2003; Perry 2001; Rajan et al. 2010; Wieczorek 1988) . In this gene family, TPM1 being the most versatile, comprises 15 exons and encodes a variety of tissue specific isoforms. Two major striated and smooth muscle isoforms, a-Tm and b-Tm are encoded by TPM1 and TPM2, respectively, whereas c-Tm encoded by TPM3 is expressed in slowtwitch skeletal muscles (Perry 2001; Rajan et al. 2010) .
A variety of human diseases have been linked to mutations of Tm encoding genes and differential expression of Tm isoforms (Gunning 2008; Muthuchamy et al. 1995 Muthuchamy et al. , 1998 Perry 2001; Wieczorek et al. 1988) . Recently, Denz et al. discovered a novel isoform, j-Tm, also encoded by the TPM1 gene, in human cardiac muscle using an RT-PCR-based strategy (Denz et al. 2004 ). Subsequently, this cardiac-specific protein isoform was found to be up-regulated in the left ventricles of patients with dilated cardiomyopathy (DCM) and end-stage heart failure (Rajan et al. 2010) . The data from Vieczorek's group also indicated that altered phosphorylation may be a significant factor when linking Tm mutation (Glu54Lys) to DCM (Warren et al. 2008) . Moreover, a recent study showed that p38-MAPKmediated dephosphorylation of a-Tm in murine hearts resulted in decreased contractility (Vahebi et al. 2007) . Although a-Tm (encoded by TMP1) has been confirmed to be the predominant Tm isoform in the human heart (Rajan et al. 2010 ), a thorough analysis of Tm isoforms and their associated PTMs is still lacking. Hence, to better understand the role of Tm in cardiac function, complete characterization of human Tm isoforms and their PTMs is needed.
Recently, our group developed a top-down mass spectrometry (MS)-based targeted proteomics approach that enables comprehensive study of Tm isoforms and PTMs from swine heart tissue (Peng et al. 2013) . Unlike bottom-up proteomics, top-down MS detects intact proteins without digestion, thereby offering an ''bird's eye view'' of all protein modifications including isoforms, mutations, and PTMs simultaneously in one MS spectrum without a priori knowledge (Ayaz-Guner et al. 2009; Dong et al. 2012; Ge et al. 2009; Peng et al. 2012 Peng et al. , 2013 Roth et al. 2005; Ryan et al. 2010; Siuti and Kelleher 2007; Xu et al. 2011; Zabrouskov et al. 2008; Zhang and Ge 2011; Zhang et al. 2011a, b) . Subsequently, individual protein species (isoforms or post-translationally modified species) can be ''gas-phase'' isolated and fragmented by tandem MS techniques (MS/MS) such as collision-induced dissociation (CID) (Senko et al. 1994 ) and electron capture dissociation (ECD) (Zubarev et al. 2000) in order to obtain sequence data or localize PTM sites.
Herein, we have employed top-down MS-based targeted proteomics to characterize Tm purified from human donor hearts with normal cardiac function. We have improved our Tm purification method and now only *5 mg of cardiac tissue is needed to purify Tm in less than 3 h. Our MS data identified several human Tm isoforms expressed in human heart tissue and mapped PTMs including acetylation and phosphorylation. Moreover, we discovered regional variations in the expression of specific Tm isoforms in human donor hearts.
Methods

Chemicals and reagents
All the reagents were purchased from Sigma Chemical Co. (St. Louis, MO, USA) unless noted otherwise. All the solutions were made in Milli-Q water (Millipore, Corp., Billerica, MA, USA).
Human heart tissue samples All the human heart tissue samples (clinical characteristics in Supplemental Table 1 
Purification of human Tm
A rapid purification method was used to purify Tm from human hearts as described previously (Peng et al. 2013) with improvements (Fig. 1a) . In this study, a much smaller amount of tissue (*5 mg) was used for Tm extraction and purification compared to that of swine Tm (100-400 mg). Briefly, approximately 5 mg of heart tissue was homogenized in 50 lL of HEPES extraction buffer (Neverova and Van Eyk 2002) [HEPES, 25 mM, pH 7.5, NaF, 50 mM, Na 3 VO 4 0.25 mM, PMSF (in isopropanol), 0.25 mM, EDTA, 2.5 mM] using a Teflon pestle (1.5 mL tube Rounded tip, Cienceware, Pequannock, NJ, USA). The homogenate was centrifuged at 16,100 g at 4°C for 15 min (Centrifuge 5415R, Eppendorf, Hamburg, Germany) and the supernatant was discarded. The pellet was then homogenized in 50 lL of TFA extraction buffer (TFA 1 %, TCEP, 1 mM) using the same Teflon pestle. The homogenate was centrifuged (16,100 g, 4°C, 15 min) to collect the supernatant (*45 lL). Ten percent NH 4 OH was added to the collected supernatant drop-by-drop until the supernatant was neutralized at pH *7.0. Precipitation occurred during the neutralization process and the mixture was then centrifuged at 16,100 g, 4°C for 2 min to remove the precipitate. Finally, the supernatant was desalted using the Amicon 100 kDa molecular weight cutoff (MWCO) filter and 0.1 % formic acid solution. The entire purification process of Tm took less than 3 h. Protein content in fractions was characterized by SDS-PAGE on 12.5 % polyacrylamide gels stained with Coomassie Blue (Fig. 1b) .
Top-down MS
Purified human Tm (Tm *20 lg/mL, methanol:water: acetic acid = 47:47:6) was analyzed using a 7 T linear ion trap/Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (LTQ/FT Ultra, Thermo Scientific Inc. Bremen, Germany) equipped with an automated chip-based nano ESI source (Triversa NanoMate; Advion Bioscience, Ithaca, NY, USA) as described previously (Peng et al. 2013) . Tm sample was introduced into the mass spectrometer using a spray voltage of 1.3-1.5 kV versus the inlet of the mass spectrometer, generating a flow rate of 50-200 nL/min. The resolving power of FT-ICR full MS analysis was typically set at 400,000. For CID and ECD, the protein molecular ions of individual charge states were first isolated and then fragmented using 12-20 % normalized collision energy (CID) or 2.2-3.0 % electron energy (ECD, corresponding to 1.0-18 eV) with a 70 ms duration and no additional delay. In this study, typically, 1,000-4,000 scans were averaged to ensure high-quality CID and ECD spectra. All MS and MS/MS spectra were analyzed by inhouse developed MASH Suite software (version 1.0) using the THRASH algorithm with S/N threshold of 3 and a minimum fit of 60 % and then manually validated. The fragment ions in MS/MS spectra were assigned based on the protein sequence of human Tm isoforms obtained from Swiss-Prot database (UnitProtKB/Swiss-Prot). Allowance was made for possible PTMs such as acetylation of the N-terminus and phosphorylation using 10 ppm tolerance for the precursor and fragment ions, respectively. For the fragment ions containing possible phosphorylation sites, a mass shift *80 Da was manually validated to confirm or exclude the existence of phosphorylation. All the reported molecular weights (MWs) of intact proteins were the most abundant MWs (the most intense peak in the isotopic distribution) and those of fragment ions were monisotopic MWs.
Quantitative analysis of major human Tm isoforms and their phosphorylation present in four different chambers of human heart samples were performed as described previously (Dong et al. 2012; Peng et al. 2013; Zhang and Ge 2011) . For each detected protein form, the sum of the peak heights of the top five isotopomers was used to calculate the relative abundance. The percentages of a-, b-, j-Tm, and mono-phosphorylated a-Tm ( p a-Tm) were defined as the abundances of a-, b-, j-, and p a-Tm over the summed abundances of the entire human Tm populations, respectively. The phosphorylation occupancy was calculated as the abundance of the phosphorylated a-Tm over the summed abundance of the total a-Tm population. Minor degradation products and non-covalent phosphate adducts (?H 3 PO 4 ) were also taken into account in the quantification.
Statistical analysis
Six donor hearts and four different chambers from three of those heart samples were investigated in this study (Supplementary Table 1 ). Specifically, the de-identified case numbers for the three hearts with tissue from four chambers are 9762, 10108, 9759, and three hearts with tissue from only one chamber are 9773, 9757 and 9774, respectively. Data were represented as mean ± SEM. Student's t tests were performed between group comparisons to evaluate statistical significance of variance. Differences among means were considered significant at p \ 0.05.
Results
SDS-PAGE and high-resolution MS of human Tm
Tm was extracted and purified from human heart tissue and analyzed by SDS-PAGE (Fig. 1b) . The purified Tm collected after desalting with 100 kDa MWCO (''purification'') was used for further MS analysis (Fig. 1a) . Although numerous bands were observed in the HEPES and TFA extractions, only one major band was detected in the purification with a MW *32 kDa (Fig. 1b) , indicating a highly efficient purification of Tm from human heart tissue. SDS-PAGE analysis of two parallel extractions from the same tissue samples (''extraction replicates'') demonstrated the reproducibility of this purification method. FT-ICR MS analysis with high-resolution and high mass accuracy provides an overview of all detectable protein forms present in human Tm ( Fig. 2 and Supplementary Figures 1  and 2 ). High-resolution MS spectra of purified human Tm from different donor hearts exhibited comparable profiles and the protein form with MW of 32749.92 was the predominant peak in those spectra, corresponding to the major human Tm isoform, a-Tm (P09493, TPM1_HUMAN, UniProtKB/Swiss-Prot) with the consideration of one acetylation (?42 Da) (Supplementary Figure 3) . Since N-terminal acetylation is prevalent in eukaryotic proteins, it was reasonable to assume this modification occurs to human Tm. The peak next to it, with a MW of 32829.88 and a mass discrepancy of 79.96 Da, was assigned as the mono-phosphorylated form of the predominant peak, p a-Tm. We also noticed that a peak with a mass discrepancy of 141.88 (MW, 32891.80) from the predominant Tm isoform was detected in the spectra, which is assigned as human b-Tm based on accurate MW match (3.0 ppm) with N-terminal acetylation (Table 1 ). In addition, a peak with experimental MW of 32971.75 can be observed in some human hearts, of which the MW matched with that of mono-phosphorylated b-Tm (Calc'd: 32971.58). Interestingly, the experimental MW of a very minor peak (Expt'l: 32690.88) matched the theoretical value (Calc'd: 32690.70) of a novel isoform, j-Tm, as reported by Rajan et al. (2010) . Subsequently, we have performed MS/MS to confirm the sequences of a-, b-and j-Tm isoforms (vide infra)
In addition, we have observed a trace amount of degradation products in the spectra, of which the MWs matched with the C-terminal degradation products of aTm, , and , respectively (Table 1) ; however, due to the low abundances of these peaks in the donor heart samples, MS/MS was not performed in this study. We also detected minor peaks with MWs of 32861.80, 33017.07, 33067.70 and 33078.25 in some but not all human heart samples. Nonetheless, these peaks were not present consistently in the spectra so we cannot confidently assign them. Intriguingly, the experimental MW of one of these unassigned peaks, 32861.80, bears a mass discrepancy of 2 Da compared to the calculated MW of human c-Tm, 32859.79 (P06753, TPM3_HUMAN, UniprotKB/Swiss-Prot) with acetylation at the N-terminus (Supplementary Figures 2-3) . c-Tm encoded by TPM3 is known to be expressed in slow-twitch skeletal muscles (Perry 2001; Rajan et al. 2010) but not in cardiac muscles. Due to the large mass error (2.01 Da corresponds to 60 ppm) which greatly exceeded the typical error (1-10 ppm) observed from our high-resolution high accuracy mass spectrometer (7T LTQ/FT), we cannot confidently assign this peak as c-Tm. Further MS/MS experiments will need to be performed to characterize the sequence of this isoform.
Sequencing major human Tm isoform
After considering of a potential acetylation (42.01), the experimental MW value of the predominant peak 32749.92 (Fig. 3a) matched well with calculated MW of a-Tm (P09493, TPM1_HUMAN, UniProtKB/Swiss-Prot) (32707.73 ? 42.01 = 32749.74) (5.5 ppm). To confirm the possible modifications and sequence of a-Tm, the precursor ions of specific charge states of human a-Tm were isolated individually and then fragmented by both ECD and CID. We have collected a total of 5 ECD and 4 CID spectra from multiple charge states (M ) of human a-Tm, respectively. The MS/MS data unambiguously confirmed the sequence of human a-Tm (P09493) with N-terminal acetylation. As shown in Fig. 3b , 104 c and 64 zÁ ions from ECD spectra as well as 69 b and 12 y ions from CID spectra were observed, which matched the Motil (2013) 34:199-210 203 predicted value of the fragment ions from the sequence of human a-Tm (P09493) with N-terminal acetylation. Please note that c and b ions are counted from the N-terminus and y and zÁ ions from the C-terminus. Extensive sequencing by both ECD and CID data rendered 185/283 cleavage bonds of a-Tm (Fig. 3b, c) . Thus, top-down MS-based proteomics provided highly accurate mass measurement and effective sequencing of human a-Tm.
Localizing the phosphorylation site of human a-Tm
As shown in Fig. 2 , the peak with a mass discrepancy of 79.96 Da (MW: 32829.88) from the predominant peak (MW: 32749.92) was assigned as mono-phosphorylated form of human a-Tm. No bis-or tris-phosphorylated form of human a-Tm was detected in the MS spectra. To map the phosphorylation site of human a-Tm, the precursor ions of a single charge state of mono-phosphorylated a-Tm ( p a-Tm) were isolated and fragmented by ECD. Hundred c ions and 51 zÁ ions were detected from four combined ECD spectra of p a-Tm. Figure 4 demonstrated the representative fragment ions and complete ion product map of mono-phosphorylated a-Tm. As shown in Fig. 4 , no phosphorylated c ions were observed whereas all the zÁ ions were phosphorylated, suggesting that phosphorylation occurred near the C-terminus of the protein. Since the smallest phosphorylated fragment ion obtained was zÁ 11 , the phosphorylation site can be localized to one of the first 11 amino acid at the C-terminus. According to the C-terminal sequence (DHALNADTSI), there were only one serine (Ser283) and one threonine (Thr282) which are likely to be phosphorylated. Indeed, Ser283 is known as the phosphorylation site as reported in the previous studies of Tm (Houle et al. 2007; Mak et al. 1978 ).
Confirmation of human b-Tm by top-down MS
As discussed above, we detected a Tm isoform (32891.86, Supplementary Figure 4A ) with a mass discrepancy of 141.88 Da from the predominant a-Tm (32749.92), which is comparable to the same mass discrepancy exhibited between swine a-Tm and b-Tm (Peng et al. 2013 ). Thus, we hypothesized this isoform as human b-Tm and then characterized it using MS/MS method. MS/MS of this isoform confirmed that the sequence of this isoform Sequence characterization of human j-Tm
We screened six donor heart samples from Wisconsin Donor Network (Supplementary Table 1 ). An interesting peak with MW of 32690.88 was detected in the human Tm spectra (Fig. 5a ). This peak had a mass discrepancy of -59.04 Da from the predominant a-Tm, suggesting that it may be another isoform of human Tm instead of modification or degradation of a-Tm.
To fully characterize this interesting isoform, the precursor ions of a single charge state were isolated and fragmented by CID experiments. Thirty-six b ions and 16 y ions were detected from two combined CID spectra (Fig. 5b,  Supplementary Figure 5 ) and representative fragment ions are shown in Fig. 5c , which unambiguously confirmed the sequence of human j-Tm. Meanwhile, highly accurate mass measurement of this isoform demonstrated that its experimental MW (32690.88) matched well with the calculated value of human j-Tm from Swiss-Prot database (P09493-6, TPM1_HUMAN, UniProtKB/Swiss-Prot) with acetylation at the N-terminus (32648.69 ? 42.01 = 32690.70).
Relative quantification of Tm isoforms in human heart four chambers
In our sample screening process, we noticed that the protein level of j-Tm in LA was much higher than that expressed in RV of donor heart samples (Fig. 2, 9759LA , 9773LA, 9762RV, 10108RV, 9759RV, 9757RV, 9774RV). This observation led us to hypothesize that heterogeneity of human Tm expression exists across the chambers of hearts. Indeed, we did find that there were regional differences in the expression of Tm as shown in the representative full MS spectra of human Tm protein species (isoforms/phosphorylated forms) from the right atrium (RA), LA, RV, and left ventricle (LV) of one human donor heart (Fig. 6a) . To quantify the relative expression levels of human Tm isoforms/phosphorylated species in different chambers of human heart, the percentages of human a-Tm, p a-Tm, b-Tm and j-Tm were calculated based on the molecular ion abundance of Tm purified from three donor hearts with all four chamber tissue samples available (Supplementary Figure 6) . The percentages of human a-Tm, p a-Tm, b-Tm and j-Tm in different heart chambers are shown in Fig. 6b -e. Human a-Tm was the predominant form in four chambers with percentage of 66.0 ± 4.0 % (RA), 61.5 ± 5.9 % (LA), 71.4 ± 2.7 % (RV) and 68.9 ± 4.4 % (LV), respectively (Fig. 6b) . The percentages of phosphorylated a-Tm ( p a-Tm) over the entire Tm population was 23.4 ± 4.7 % (RA), 21.7 ± 3.0 % (LA), 12.3 ± 0.7 % (RV) and 11.7 ± 2.2 % (LV), respectively (Fig. 6c) . Moreover, the percentages of human b-Tm isoform over the entire Tm population were 5.5 ± 0.6 % (RA), 6.0 ± 2.1 % ). b Fragmentation ion map of j-Tm from CID data. Fragment assignments were made to the DNA-predicted sequence of human j-Tm (P09493-6, TPM1_HUMAN, UniProtKB/ Swiss-Prot) with acetylation at the N-terminus (42.01). c Representative b ions from CID data. Expt'l, experimental molecular weight. Calc'd, calculated molecular weight (LA), 5.1 ± 0.9 % (RV) and 6.7 ± 0.7 % (LV), respectively (Fig. 6c) . Notably, the percentages of j-Tm isoform were 1.4 ± 1.4 % (RA), 3.0 ± 0.6 % (LA) and 0.5 ± 0.5 % (RV), whereas no j-Tm was detected in LV of all the human donor hearts (Fig. 6e) . The relatively large standard errors of j-Tm percentage in RA and RV were due to the fact that j-Tm was only detected in 1 out of 3 samples. The phosphorylation occupancy of a-Tm ( p a-Tm/a-Tm) in four chambers was 35.9 ± 7.9 % (RA), 36.8 ± 7.7 % (LA), 17.3 ± 0.8 % (RV) and 17.1 ± 2.9 % (LV), respectively (data not shown).
Discussion
In this study, we have confirmed the presence of multiple Tm isoforms including a-Tm, b-Tm and j-Tm in the human heart, with a-Tm being the predominant isoform, followed by minor isoforms of b-Tm and j-Tm. Moreover, we have investigated the regional variations of Tm isoforms and PTMs in different chambers of the human heart. We found that the expression level of j-Tm was highest in LA followed by RA and RV, but nearly undetectable in LV. Furthermore, we found that the phosphorylation level of a-Tm ( p a-Tm) was significantly higher in the atria than it was in the ventricles. The sequences of all Tm isoforms and the PTM sites were unambiguously characterized by top-down MS.
Tms are a family of actin binding proteins that are encoded by four genes (TPM1, TPM2, TPM3, and TPM4), which can give rise to a variety of tissue specific isoforms through alternative splicing events. By comparison, the human TPM1 gene is far more versatile than swine TPM1 in that a greater number of distinct isoforms can be produced via alterative splicing of the human TPM1 transcript. As shown in (Supplementary Figure 7A) , seven different isoforms of human Tm, which are expressed in different Fig. 6 Quantification of human Tm isoforms present in four chambers of donor human hearts. a MS spectra of human Tm isoforms in four chambers. a-d RA, LA, RV and LV of the donor heart 9759. Relative quantification of Tm isoforms b a-Tm, c p a-Tm, d b-Tm, and e j-Tm in four heart chambers, n = 3, from three donor hearts (9759, 10108, 9762) . Single and double stars represent noncovalent adducts of phosphoric acid (?H 3 PO 4 , and 2?H 3 PO 4 ), respectively. The data were expressed as mean ± SEM. *p \ 0.05 J Muscle Res Cell Motil (2013) 34:199-210 207 muscle types, are encoded by TPM1. Of these isoforms, only a-Tm and j-Tm have been identified in human cardiac muscle (Rajan et al. 2010) . j-Tm was reported to contain exon 2a among 15 exons of TPM1 instead of 2b in a-Tm expressed in human cardiac tissues (Denz et al. 2004) . In this paper, we confirmed that both a-Tm and j-Tm are expressed in human cardiac tissues and comprehensively characterized their sequences (Figs. 3, 4 , 5, Supplementary Figure 7B) . The difference between TPM1 encoded j-mRNA and TPM1 encoded a-mRNA was a stretch of 40 amino acids encoded by exon 2a/b (Rajan et al. 2010) . The top-down MS-based targeted proteomic analysis confirmed that the sequences of the a-and j-isoforms were highly similar with the only amino acid difference between these isoforms located in the N-terminus (Supplementary Figure 7B) . Previous studies have demonstrated that cardiac structure and function can be dramatically altered via changes in the expression levels of different Tm isoforms. In the adult healthy mouse heart the protein expression level of b-Tm is less than 2 %. When there was 55-60 % of b-Tm present in the myocardium of transgenic mouse heart, the time of relaxation, maximum rate of relaxation and sensitivity to calcium changed significantly (Muthuchamy et al. 1998 (Muthuchamy et al. , 1995 Palmiter et al. 1996; Wieczorek et al. 1988) . Further altering of b-Tm to an even higher level (b-Tm/a-Tm = 80/20) in the heart of transgenic mice will cause postnatal death between 10 and 14 days (Muthuchamy et al. 1998; Wieczorek et al. 2008) . In contrast, high expression level of c-Tm (40-60 %) can lead to hyperdynamic effect on systolic and diastolic function and decreased calcium sensitivity (Jagatheesan et al. 2010a) . Recently, a novel isoform, j-Tm encoded by TPM1 was reported to be expressed in human cardiac muscle (Denz et al. 2004 ) using a j-Tm specific antibody. j-Tm was shown to be expressed in healthy human hearts (*3-5 %) and up-regulated in human LV free walls of DCM and heart failure patients (Rajan et al. 2010) . The ratio of b-Tm to a-Tm in healthy pig heart was much higher than that reported in healthy mouse heart, which means that isoform expression can also differ across species (Peng et al. 2013) . Here, we have observed a small amount of b-Tm and j-Tm in the human donor hearts (Figs. 2, 6) .
In this paper, we investigated for the first time on regional variations of human Tm isoforms in four chambers of normal human heart. Our MS data demonstrated that a-Tm (nonphosphorylated and mono-phosphorylated a-Tm) was the predominant isoform, constituting 84.2 % of the total Tm population. Interestingly, the phosphorylation occupancy of human a-Tm in the four heart chambers was significantly different. As shown in Fig. 6c , the expression level of phosphorylated a-Tm ( p a-Tm) present in the atria (RA and LA) was similar, but was twofold greater than it was in the ventricles (RV and LV), which means more a-Tm was phosphorylated in atrium compared to that in ventricle of human donor heart (p \ 0.05). Meanwhile, b-Tm occupies *3-8 % of whole Tm population in human cardiac tissues with no significant difference observed in different chambers (Fig. 3d) . Interestingly, we found j-Tm was not equally distributed in the four heart chambers. Notably, j-Tm has the highest expression level in LA than that in other heart chambers (Fig. 6e) . Hence, to compare the expression level of human cardiac isoforms, it is necessary to take chamber heterogeneity into consideration.
The heterogeneity of Tm isoforms as well as diverse PTMs occurred to those isoforms makes it difficult to conduct a comprehensive study of Tm molecular forms by traditional methods such as Western blot. To distinguish one Tm isoform from the other, isoform-specific antibodies need to be developed for quantitative analysis. For example, to quantify j-Tm, Rajan et al. developed an isoformspecific antibody which has an epitope that recognizes residues within the exon 2a sequence of j-Tm (Rajan et al. 2010) . However, antibody development is not only timeconsuming but also of variable success because some antibodies are highly specific whereas others are not, especially for a large family of isoforms encoded by different genes with variant sequences, distinct conformations and diverse PTMs.
In contrast to antibody-based Western blot analysis, topdown MS is a universal detection method which can provide an overview of all types of isoforms of the protein of interests from different encoded genes, alternative splicing and PTMs in one spectrum without prior knowledge (Ayaz-Guner et al. 2009; Dong et al. 2012; Ge et al. 2009; Peng et al. 2012 Peng et al. , 2013 Roth et al. 2005; Ryan et al. 2010; Siuti and Kelleher 2007; Xu et al. 2011; Zabrouskov et al. 2008; Zhang and Ge 2011; Zhang et al. 2011a ). Thus, top-down MS is an attractive and unique tool for the analysis of protein isoforms and PTMs (Roth et al. 2005; Sancho Solis et al. 2008; Zhang and Ge 2011; Zhang et al. 2011a ). Moreover, top-down MS combined with ECD and CID offers comprehensive sequencing of proteins to nail down the sequence variations and PTM sites to a single amino acid (Ayaz-Guner et al. 2009; Peng et al. 2013; Xu et al. 2011) . In this study, we have shown that top-down MS can identify various human Tm isoforms and their modifications in one MS spectrum (Fig. 2 , Supplementary Figure 2 ). MS/MS sequencing of the isoforms could unambiguously confirm the sequences and map the modification sites. This top-down MS-based proteomic approach required only 5 mg of heart tissue and the entire purification process takes less than 3 h, which significantly reduced the amount of tissue demanded and greatly increased the throughput. Moreover, it eliminates the need for specific antibodies. Thus, top-down MS is an attractive method for in-depth characterization of Tm isoforms and PTMs with high reproducibility and throughput.
